Skip to main content
    O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.01
    -0.20 (-3.22%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ocular Therapeutix Inc (OCUL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Ocular Therapeutix are Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA) and Theravance Biopharma (TBPH). By market cap, Ocular Therapeutix ranks 6th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    OCUL's ROIC of -52.1% is below the peer median of -51.1%, and its revenue growth of -11.5% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Ocular Therapeutix (OCUL)$1.37BN/A26.9x0.0%-52.1%-11.5%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Mineralys Therapeutics, Inc. Common Stock (MLYS)$1.36BN/AN/A0.0%-51.1%0.0%0.00%
    Trevi Therapeutics Inc (TRVI)$1.95BN/AN/A0.0%N/A0.0%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Omeros Corporation (OMER)$1.27BN/A16.4x324.9%33.6%14.9%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Oculis Holding AG Ordinary shares (OCS)$425.67MN/AN/A0.0%N/A-97.1%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Peer median$1.32B95.1x20.1x0.0%-51.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Ocular Therapeutix, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Mineralys Therapeutics, Inc. Common Stock (MLYS)
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular...
    MLYS competitors
    Trevi Therapeutics Inc (TRVI)
    Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious...
    TRVI competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    Omeros Corporation (OMER)
    Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies...
    OMER competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Oculis Holding AG Ordinary shares (OCS)
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
    OCS competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors

    Frequently Asked Questions About OCUL

    Who are Ocular Therapeutix's main competitors?

    The companies most similar to Ocular Therapeutix include Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA), Theravance Biopharma (TBPH), Vera Therapeutics (VERA) and Mineralys Therapeutics, Inc. Common Stock (MLYS), listed from the closest match.

    Who is Ocular Therapeutix's biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.

    How does OCUL stock compare with its competitors?

    OCUL's P/S is 26.9x against a peer median of 20.1x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Ocular Therapeutix's competitors pays a higher dividend?

    Ocular Therapeutix pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Ocular Therapeutix bigger than its competitors?

    No. Ocular Therapeutix is 6th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.